Bruce Powers says in a recent news release that thanks to an international collaboration between them, Isogen and ITM Isotope Technologies Munich a milestone marking the first instance of lutetium -177 a short-living medical isotope has been produced in a commercial nuclear power reactor.
It was achieved using a new Isotope Production System installed in Bruce Power’s Unit 7 during a recent planned maintenance outage.
The IPS successfully irradiated targets to produce the isotope used in precision oncology for targeted therapy of a growing number of cancers.
Treatments based on this isotope are designed to precisely target malignant cells while sparing surrounding healthy tissues.
